8-K: Teknova Reports 17% Revenue Growth in Q3 2024, Lowers Free Cash Outflow Outlook

Alpha Teknova, Inc. announced a 17% year-over-year revenue increase for the third quarter of 2024 and lowered its free cash outflow outlook for the year.

Summary

• Teknova's third quarter 2024 revenue reached $9.6 million, a 17% increase compared to $8.2 million in the same quarter of 2023.
• The company's Clinical Solutions revenue saw a significant jump, increasing by 229% to $2.0 million, while Lab Essentials revenue remained relatively flat at $7.2 million.
• Gross profit for the quarter was $0.1 million, down from $1.5 million in the prior year, primarily due to a $2.8 million non-recurring charge related to inventory disposal.
• Excluding this charge, the gross margin would have been 29.8%.
• Operating expenses decreased to $7.5 million from $10.2 million in the third quarter of 2023, driven by reduced headcount and spending.
• Net loss for the quarter was $7.6 million, or negative $0.15 per diluted share, compared to a net loss of $10.2 million, or negative $0.34 per diluted share, in the third quarter of 2023.
• Adjusted EBITDA was negative $5.0 million, or negative $2.2 million excluding the $2.8 million charge.
• Free cash flow was negative $2.4 million for the quarter, compared to negative $5.4 million in the same period last year.
• Teknova reaffirmed its 2024 revenue guidance of $35-38 million and lowered its free cash outflow outlook to less than $16 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong revenue growth and improved cash flow, but tempered by the net loss and non-recurring charges. The company is showing progress but still has challenges to overcome.

Positives

• Teknova achieved a 17% year-over-year increase in total revenue for the third quarter of 2024.
• The Clinical Solutions segment experienced substantial growth, with a 229% increase in revenue.
• The company successfully reduced operating expenses by $2.3 million year-over-year, excluding non-recurring charges.
• Free cash flow improved significantly, decreasing from negative $5.4 million to negative $2.4 million year-over-year.
• Net loss per share improved from negative $0.34 to negative $0.15 year-over-year.
• The company lowered its free cash outflow outlook for 2024 from less than $18 million to less than $16 million.

Negatives

• Gross profit decreased significantly due to a $2.8 million non-recurring charge related to inventory disposal.
• The reported gross margin for the third quarter was only 0.9%, although it would have been 29.8% excluding the non-recurring charge.
• The company reported a net loss of $7.6 million for the quarter.
• Adjusted EBITDA was negative $5.0 million for the quarter, or negative $2.2 million excluding the non-recurring charge.

Risks

• The company experienced a $2.8 million non-recurring charge related to the disposal of expired inventory and write down of excess inventory.
• Teknova's revenue is subject to fluctuations, with a typical softening in the fourth quarter due to fewer business days.
• The company's future performance is subject to risks related to demand for its products, supply chain, and global economic uncertainties.
• The company relies on a limited number of customers for a high percentage of its revenue.

Future Outlook

Teknova reaffirms its 2024 revenue guidance of $35-38 million and lowers its free cash outflow outlook to less than $16 million. The company anticipates roughly 2% growth in Lab Essentials and expects to build on the current momentum into 2025.

Management Comments

• Stephen Gunstream, President and Chief Executive Officer, stated that the year-on-year double-digit revenue growth in the third quarter gives them confidence that Teknova is on track for long-term success.
• Stephen Gunstream believes that the difficult decisions made to reduce expenses and raise modest amounts of capital are beginning to bear fruit.
• Matt Lowell, Teknova's Chief Financial Officer, explained that they typically see revenue soften in the fourth quarter and are maintaining their full-year outlook while lowering their free cash outflow outlook.

Industry Context

Teknova's focus on critical reagents for the life sciences industry aligns with the growing demand for novel therapies, vaccines, and molecular diagnostics. The company's growth in Clinical Solutions reflects the increasing importance of this segment in the broader biotech market.

Comparison to Industry Standards

• While Teknova's 17% revenue growth is positive, it's important to compare it to peers in the life sciences reagents market. Companies like Thermo Fisher Scientific and Danaher often report single-digit growth rates, but they are much larger and more established.
• The significant improvement in free cash flow from negative $5.4 million to negative $2.4 million is a positive sign, but the company still needs to achieve positive cash flow to be considered financially stable.
• The non-recurring charge of $2.8 million highlights the challenges of inventory management in the biotech industry, which is a common issue for companies scaling up production.
• Teknova's adjusted EBITDA of negative $5.0 million, or negative $2.2 million excluding the non-recurring charge, is not unusual for a growth-stage biotech company, but it needs to show a clear path to profitability.

Stakeholder Impact

• Shareholders will likely react positively to the revenue growth and improved cash flow outlook.
• Employees may be impacted by the reduced headcount and spending, but the company's long-term growth strategy could provide future opportunities.
• Customers should benefit from the company's continued focus on providing high-quality reagents.
• Suppliers may see increased demand as the company continues to grow.

Next Steps

• Teknova will attend the Stephens Annual Investment Conference on November 20, 2024.
• The company will host a webcast and conference call on November 7, 2024, to discuss the financial results.

Key Dates

Keywords

revenue, financial results, clinical solutions, lab essentials, gross margin, EBITDA, free cash flow, operating expenses, net loss, inventory, reagents, biotech